| Field | Specification |
|---|---|
| Target | |
| Alternative names | Collagen alpha-1 (I) chain;Alpha-1 type I collagen;Col1a1;Cola1; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of mouse Collagen I, identical to the related rat sequence, and different from the related human sequence by two amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects collagen alpha-1(I) chain (gene Col1a1) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 138.0 kDa; the supplier reports observed bands at 130 kDa, 220 kDa, 250 kDa.
Collagen α1(I) chain (COL1A1) is the major chain of type I collagen, the most abundant fibrillar collagen in bone, skin, tendon and other connective tissues. It is a standard marker of fibroblasts, osteoblasts and fibrosis, and COL1A1 mutations cause osteogenesis imperfecta.
| Target | Collagen alpha-1(I) chain (gene Col1a1; UniProt P11087, mouse) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 138.0 kDa |
| Observed MW | 130 kDa, 220 kDa, 250 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 1–2 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Mouse) |
Samples with a confirmed band (WB): human placenta tissue, rat skin tissue, mouse skin tissue, mouse NIH/3T3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 8% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human bladder cancer tissue, human esophageal squamous cells carcinoma tissue, human clear cells renal cells carcinoma tissue, human placenta tissue, human rectum adenocarcinoma tissue, mouse lung tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human endometrial cancer tissue, human intestinal cancer tissue, rat lung tissue.
Samples with confirmed staining (ICC/IF): NIH/3T3 cells.
Immunogen
Synthetic peptide from the C-terminal region of mouse collagen I. The peptide sequence is conserved in rat. It differs from the human sequence at two residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. Tissue expression noted by UniProt (mouse): Forms the fibrils of tendon, ligaments and bones. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Patrick K. Jaeger et al. (2025) Matrix and cytoskeletal tension gate stretch-induced calcium signaling. Acta Biomaterialia. 10.1016/j.actbio.2025.09.014
Erlinda The et al. (2024) Molecular Interaction of Soluble Klotho with FGF23 in the Pathobiology of Aortic Valve Lesions Induced by Chronic Kidney Disease. International Journal of Biological Sciences. 10.7150/ijbs.92447
Zhang Peijian et al. (2022) Pro-inflammatory mediators released by activated monocytes promote aortic valve fibrocalcific activity. Molecular Medicine. 10.1186/s10020-022-00433-4
Lombardi Francesca et al. (2022) Efficacy of probiotic Streptococcus thermophilus in counteracting TGF-β1-induced fibrotic response in normal human dermal fibroblasts. Journal of Inflammation-London. 10.1186/s12950-022-00324-9
Sharma Archana et al. (2023) Extracellular matrix composition affects outgrowth of dendrites and dendritic spines on cortical neurons. Frontiers in Cellular Neuroscience. 10.3389/fncel.2023.1177663
Katherine E. Hill et al. (2021) Heparan sulfate is necessary for the early formation of nascent fibronectin and collagen I fibrils at matrix assembly sites. Journal of Biological Chemistry. 10.1016/j.jbc.2021.101479
Ching-Lung Wu et al. (2025) Depletion of tropomyosin 1.6 alleviates TGF-β1-induced fibroblast activation by promoting the α-SMA-MMP9 matrix-degrading structure. iScience. 10.1016/j.isci.2025.113317
Özdem Tayfun et al. (2026) Modulatory effects of 6-Gingerol on erythrocyte deformability and morphology following lower extremity skeletal muscle ischemia-reperfusion injury in rats. Scientific Reports. 10.1038/s41598-026-36365-w
Wanida Ruangsiriluk et al. (2025) Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. Biomedicines. 10.3390/biomedicines13030577
Natalia Boukharov et al. (2024) Developing Gene Therapy for Mitigating Multisystemic Pathology in Fabry Disease: Proof of Concept in an Aggravated Mouse Model. Human Gene Therapy. 10.1089/hum.2023.222
